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Introduction: Small-cell lung cancer (SCLC) accounts for about 20% 
of all lung cancers and it has poor prognosis. For extensive disease 
(ED), combination chemotherapy (CT) with platinum and etoposide 
is standard, with response rate of 60-80%, but the overall long-term 
survival is less than 10% (at 5 years) with a median progression-free 
survival of 4 months. Topotecan produces a response rate of about 24% 
in sensitive relapse patients (pts).
Material and Methods: The authors reviewed 146 consecutive pts 
with SCLC, diagnosed from January of 2002 to December of 2006, at 
Portuguese Institute of Oncology - Porto Center, and they evaluated 
those treated with topotecan as second-line CT, regarding topotecan’s 
efﬁcacy and toxicity.
Results: From 146 pts reviewed, 23 were treated with topotecan as 
second-line CT. 91% were male, the median age was 59 years (range: 
23-73) and all of them were smokers or ex-smokers. At time of diagno-
sis, 78% had ED treated with platinum and etoposide; 22% had limited 
disease treated with platinum and etoposide plus thoracic radiotherapy. 
The median time from ﬁrst line treatment to progression was 7.6 
months. At beginning of second-line treatment with topotecan, 74% 
had a performance status (PS) less than 2 and 26% had a PS of 2. It 
was used the standard regimen i.v. topotecan at a dose of 1,5 mg/m2 on 
days 1-5 of a 21 day cycle. The mean of number of cycles of topotecan 
done was 3.4 with a range of 1 to 6. Topotecan’s disease control was 
31.8% (partial response - 4 pts, stable disease - 3 pts) and median time 
to progression was 2.6 months. Topotecan grade 3 toxicities described 
were: anemia in 5 pts, trombocitopenia in 4 pts, neutropenia in 3 pts 
and vomiting in 1 pt. It was described 2 cases of febrile neutropenia. 
Median overall survival was 18.2 months.
Conclusion: Topotecan has clinical activity in pts with relapsed SCLC, 
with acceptable toxicity. In this serie of our current daily practice pts, 
disease control, median time to progression and median overall survival 
were comparable to other published results.
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Background: After successful induction therapy for small-cell lung 
cancer (SCLC), most patients relapse within 2 years as a result of 
emergence of drug-resistant tumor cells. This study was conducted to 
evaluate the recommended dose and activity of amrubicin (AMR) as 
2nd-or 3rd-line chemotherapy for SCLC. 
Methods: SCLC patients with measurable disease who had previously 
been treated with at least one platinum-based chemotherapy regi-
men and had an ECOG performance status of 0-2 were eligible. Two 
groups of patients were selected: i) a group to be treated with 2nd-line 
chemotherapy and ii) a group to be treated with 3rd-line chemotherapy. 
AMR was administered to both groups as a 5-minute daily intravenous 
injection of a dose of 40 mg/m2 or 35 mg/m2 for 3 consecutive days, 
every 3 weeks. 
Results: Between March 2003 and June 2006, 27 patients (2nd-line, 
40mg/m2: 13; 3rd-line, 40mg/m2: and 35 mg/m2: 7) were enrolled. 
Although the 40 mg/m2 dose of AMR was feasible (1/13 febrile neu-
tropenia and 4/13 grade 4 neutropenia) and effecitive ( 6/13 PR) in the 
2nd-line group, it had unacceptable toxicity in a 3rd-line setting (3/7 
grade 3 non-hematologic toxicities [febrile neutorpenia:2; fatigue:1] 
and 4/7 grade 4 neutropenia). The 35 mg/m2 dose of AMR had accept-
able toxicity in the 3rd-line group ( 1/7 febrile neutropenia, 1/7 grade 4 
nerutropenia) and moderate efﬁcacy (1/7 PR, 2/7 SD). 
Conclusion: AMR exhibits signiﬁcant activity as 2nd-line or 3rd-line 
chemotherapy for SCLC. The recommended dose is 40 mg/m2 in a 2nd-
line setting and 35 mg/m2 in a 3rd-line setting.
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Background: Small cell lung cancer is one of cancers with high mor-
tality rate. Etoposide/cisplatin and recently irinotecan/cisplatin have 
shown an excellent anti-tumor effect against SCLC. However, short 
response duration and rare long-term survival have been characterized 
although it has high response to combination chemotherapy. CKD-602 
(Belotecan) is a new camptothecin derivative anti-tumor agent that 
belongs to the topoisomerase inhibitors developed by Chong Kun Dang 
pharmaceutical company in Korea. Preclinical studies suggest that 
it may have greater anti-tumor activity and lower toxicity than other 
camptothecin anticancer agents.
Methods: Patients with limited stage SCLC which progressed after it 
had responded to prior chemotherapy or extensive stage SCLC, were 
included. Patients with no measurable lesions, prior chemotherapy with 
topoisomerase inhibitor such as topotecan and irinotecan were exclud-
ed. The dose and schedule of CKD-602 at 1st cycle was 0.5mg/m2/day 
for 30 min every 3 weeks and then the dose was modiﬁed according to 
the toxicity.
Results: From March 2005 to August 2006, the total numbers of reg-
istered patients were 75. Among them, 71 patients were evaluable for 
the toxicity, 50 for the response. Mean cycle was 3.7 (range, 1 - 9). The 
response rate was 69% for 1st line chemotherapy, and 33.3% for 2nd 
line chemotherapy. 73.2% and 25.3% of patients experienced grade 3-4 
neutropenia and thrombocytopenia, respectively, without a treatment-
related death.
Conclusion: CKD-602 (Belotecan), a new camptothecin analogue, 
showed activity and acceptable toxicities as a single agent in patients 
with SCLC. This study suggests that CKD-602 can be used as treat-
ment with promising response rates in SCLC.
